EBS Q2 2022 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$446M

Q2 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$240M-39.6% YoY

Gross Profit

$19M7.9% margin

Operating Income

-$76M-31.6% margin

Net Income

-$54M-22.4% margin

EPS (Diluted)

$-1.13

QoQ Revenue Growth

-22.0%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$48M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$2.7B

Total Liabilities

$1.2B

Stockholders' Equity

$1.5B

Cash & Equivalents

$358M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$240M	$398M	-39.6%
Gross Profit	$19M	$121M	-84.3%
Operating Income	-$76M	$15M	-622.8%
Net Income	-$54M	$5M	-1269.6%

Revenue Segments

Product

$237M97%

Contracts and Grants

$7M3%

Geographic Segments

UNITED STATES

$124M51%

Non-US

$119M49%